WHO and CDC stepped up Bundibugyo Ebola outbreak diagnostics as authorities raised the threat level amid concern about broader spread in the Democratic Republic of Congo. CDC’s incident manager Satish Pillai said initial GeneXpert testing was negative because it did not detect the less common Bundibugyo species; later testing supported a positive result within 24 hours once samples were available, with genomic sequencing following within another 24 hours. Officials described a rapid response approach that begins before final sequencing is complete, expanding disease detective deployment, epidemiology training in Uganda, and community healthcare worker training through partners. The report also enumerated commercial sample-to-answer options and PCR and immunoassay alternatives used for strain detection or differentiation. For the biotech industry, the immediate impact is on diagnostic demand planning—especially for cartridge-based and multiplex PCR systems designed to differentiate Ebola species and enable faster infection-control decisions in resource-constrained settings.